After FDA requests a new trial, Allarity drops a cancer drug from solo development
The US-Danish biotech Allarity Therapeutics is having to pivot its pipeline strategy after the FDA forced them to go back to the drawing board for an oncology therapy.
Allarity announced on Tuesday that the board has mandated the biotech to refocus its oncology strategy away from the development of monotherapies and toward the development of “more promising and clinically relevant combination therapies.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.